Pain Therapeutics: REMOXY Meets Primary Endpoints In Abuse Potential Study

(RTTNews) - Pain Therapeutics, Inc., (PTIE) announced top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse.

The company reported that the study demonstrated with statistical significance that both intact and chewed REMOXY were less "liked" than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High. The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.